Scarica l'app Stockscreener
15.64
2.25%
-0.36
Dopo l'orario di chiusura:
15.64
Mediwound Ltd Borsa (MDWD) Ultime notizie
MediWound to Discuss New Share Incentive Plan - TipRanks
MediWound to Report Third Quarter 2024 Financial Results - GlobeNewswire
MediWound Q3 2024 Earnings Call Scheduled for November 26: What to Expect | MDWD Stock News - StockTitan
99,994 Shares in MediWound Ltd. (NASDAQ:MDWD) Bought by ARK Investment Management LLC - MarketBeat
MediWound Ltd. (NASDAQ:MDWD) is Rosalind Advisors Inc.'s 5th Largest Position - MarketBeat
MediWound (STU:M8W) Financial Strength : 6 (As of Jun. 2024) - GuruFocus.com
How the (MDWD) price action is used to our Advantage - Stock Traders Daily
MediWound Is A Healthy Investment (NASDAQ:MDWD) - Seeking Alpha
MediWound's (NASDAQ:MDWD) investors will be pleased with their stellar 125% return over the last year - Yahoo Finance UK
Rosalind Advisors, Inc. Increases Stake in MediWound Ltd - Yahoo Finance
(MDWD) Pivots Trading Plans and Risk Controls - Stock Traders Daily
MediWound (NASDAQ:MDWD) Rating Reiterated by HC Wainwright - Defense World
Trading (MDWD) With Integrated Risk Controls - Stock Traders Daily
MediWound shares maintain buy rating on new study plans - Investing.com India
MediWound shares maintain buy rating on new study plans By Investing.com - Investing.com South Africa
MediWound (NASDAQ:MDWD) Earns Buy Rating from HC Wainwright - MarketBeat
MediWound advances EscharEx in Phase II VLU study By Investing.com - Investing.com Australia
MediWound advances EscharEx in Phase II VLU study - Investing.com India
MediWound Announces Phase II Head-to-Head Study Evaluating - GlobeNewswire
MediWound to Participate in the 2024 Maxim Healthcare Virtual Summit - The Manila Times
(MDWD) On The My Stocks Page - Stock Traders Daily
Rhumbline Advisers Purchases Shares of 8,440 MediWound Ltd. (NASDAQ:MDWD) - Defense World
Objective long/short (MDWD) Report - Stock Traders Daily
TD Cowen maintains Buy rating on MediWound shares with no price target change - Investing.com
MediWound (NASDAQ:MDWD) Stock Price Crosses Below 200-Day Moving Average of $16.99 - MarketBeat
(MDWD) Long Term Investment Analysis - Stock Traders Daily
MediWound (NASDAQ:MDWD) Shares Cross Above 50 Day Moving Average of $18.20 - MarketBeat
MediWound to Present at the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewswire
Critical Comparison: MediWound (NASDAQ:MDWD) versus Jinhua Marine Biological (OTCMKTS:JNMB) - Defense World
MediWound Ltd.'s (NASDAQ:MDWD) top owners are retail investors with 38% stake, while 28% is held by institutions - Yahoo Finance
MDWDMediWound Ltd. Latest Stock News & Market Updates - StockTitan
MediWound Ltd. Forecasted to Post Q3 2024 Earnings of ($0.49) Per Share (NASDAQ:MDWD) - MarketBeat
Brokers Set Expectations for MediWound Ltd.’s Q3 2024 Earnings (NASDAQ:MDWD) - Defense World
MediWound (FRA:M8W) Median PS Value : €30.03 (As of Aug. 24, 2024) - GuruFocus.com
MDWD (MediWound) Free Cash Flow : $-22.27 Mil (TTM As of Jun. 2024) - GuruFocus.com
HC Wainwright Reiterates Buy Rating for MediWound (NASDAQ:MDWD) - Defense World
MediWound Ltd. (NASDAQ:MDWD) Forecasted to Earn FY2027 Earnings of $1.28 Per Share - Defense World
Equities Analysts Offer Predictions for MediWound Ltd.'s FY2027 Earnings (NASDAQ:MDWD) - MarketBeat
MediWound and Vericel win FDA paediatric label expansion for NexoBrid - Medical Device Network
MediWound shares hold Buy rating with steady target on expansion By Investing.com - Investing.com Australia
MediWound Second Quarter 2024 Earnings: EPS Misses Expectations - Simply Wall St
MediWound Announces U.S. Food and Drug Administration - GlobeNewswire
Vericel, MediWound climb on FDA's expanded approval for skin treatment - XM
MediWound’s NexoBrid Gains FDA Pediatric Approval - TipRanks
MediWound Announces U.S. Food and Drug Administration Approval of NexoBrid® for the Treatment of Pediatric Patients with Severe Thermal Burns - StockTitan
MediWound shares hold Buy rating with steady target on expansion - Investing.com
3.66%
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):